Patents by Inventor Gundeep Dhillon

Gundeep Dhillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIF-1 modulator paint formulation and uses thereof
    Patent number: 10548860
    Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: February 4, 2020
    Assignees: The Board Of Trustees of The Leland Stanford Junior University, The United States Government as Represented By The Department Of Veterans Affairs, The Johns Hopkins University
    Inventors: Mark R. Nicolls, Jayakumar Rajadas, Geoffrey C. Gurtner, Xinguo Jiang, Gundeep Dhillon, Gregg L. Semenza
  • HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF
    Publication number: 20190192452
    Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
    Type: Application
    Filed: January 29, 2019
    Publication date: June 27, 2019
    Inventors: Mark R. Nicolls, Jayakumar Rajadas, Geoffrey C. Gurtner, Xinguo Jiang, Gundeep Dhillon, Gregg L. Semenza
  • HIF-1 modulator paint formulation and uses thereof
    Patent number: 10220009
    Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: March 5, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Johns Hopkins University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Mark R. Nicolls, Jayakumar Rajadas, Geoffrey C. Gurtner, Xinguo Jiang, Gundeep Dhillon, Gregg L. Semenza
  • HIF-1 Modulator Paint Formulation and Uses Thereof
    Publication number: 20150196512
    Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
    Type: Application
    Filed: August 30, 2013
    Publication date: July 16, 2015
    Inventors: Mark R. Nicolls, Jayakumar Rajadas, Geoffrey C. Gurnter, Xinguo Jiang, Gundeep Dhillon, Gregg L. Semenza